Type 1 diabetic mice are protected from acetaminophen hepatotoxicity

Area of Science:

• Hepatology
• Toxicology
• Metabolic Diseases

Background:

• Streptozotocin-induced diabetic mice show resistance to hepatotoxic agents like acetaminophen (APAP).
• Understanding the mechanisms behind this protection is crucial for managing drug-induced liver injury.

Purpose of the Study:

• To investigate the mechanisms underlying the resistance of diabetic mice to APAP-induced hepatotoxicity.
• To elucidate the roles of drug metabolism, covalent binding, and liver regeneration in this protective effect.

Main Methods:

• Diabetic and non-diabetic mice were challenged with APAP.
• Liver injury was assessed via plasma enzymes and histopathology.
• APAP pharmacokinetics, metabolism, protein binding, and glutathione levels were analyzed.
• Liver cell proliferation was measured using 3H-thymidine and PCNA staining.
• The effect of antimitotic agents on mortality was evaluated.

Main Results:

• Diabetic mice displayed significantly lower APAP-induced liver injury.
• Enhanced APAP clearance (increased CLp, Vd; decreased t1/2) was observed in diabetic mice.
• Covalent binding to proteins and glutathione depletion did not differ between groups.
• Diabetic mice showed earlier onset of liver cell proliferation (S-phase) post-APAP exposure.
• Inhibition of cell division increased mortality in diabetic mice.

Conclusions:

• Diabetes confers resistance to APAP hepatotoxicity through enhanced drug clearance and robust compensatory liver repair.
• Liver cell division and tissue regeneration play a critical role in this protective adaptation.
• These findings offer insights into managing acetaminophen toxicity and the metabolic effects of diabetes.